Background. Comprehensive and representative data on resource use are critical for health policy decision making but often lacking for human immunodeficiency virus (HIV) infection. Privacy-preserving probabilistic record linkage of claim and cohort study data may overcome these limitations.
Accurate data on costs and resource use is critical for healthcare policy decision making to better understand current and future needs in human immunodeficiency virus (HIV) care as HIV-infected individuals receiving antiretroviral therapy (ART) become older but suffer from increasing comorbid conditions [1] . Many studies on costs related to HIV are not representative and are based on data from single centers and not across all services or on aggregated data and are thus of limited value for health policy decision makers [2] .
In the United States or Switzerland, where reimbursement of healthcare is not by a unique payer, it is even more challenging to acquire representative cost data, and different sources must be used. Privacy-preserving probabilistic record linkage may be an approach to link anonymized claims data from insurants with anonymized clinical patient data records and gain a merged data set with comprehensive health resource use and clinical information [3] . In this pilot study, we matched Swiss HIV Cohort Study (SHCS) and claims data from the largest Swiss health insurer to study costs for HIV-related and non-HIV-related conditions and their main determinants, such as patient characteristics and late presentation.
METHODS

SHCS Records
The SHCS was initiated in 1988 and enrolls all HIV-infected individuals aged ≥18 years [4] . During biannual visits, clinical, laboratory, and behavioral data are collected. The cohort is representative of the Swiss HIV epidemic and includes 66% of persons with AIDS and an estimated 70% of HIV-infected individuals receiving ART [5, 6] . Participants in the SHCS have provided written informed consent for the use of biological and clinical data for SHCS projects. For this project, additional ethical approval for privacy-preserving probabilistic record linkage was obtained.
Claims Data of Swiss Health Insurer
In Switzerland health insurance by premium and copayment is mandatory for all residents and provided by several health insurance companies. Ninety-eight percent of claims are electronically processed [7] and may be identified for ambulatory care by unique provider and laboratory codes [8] and by the Anatomical Therapeutic Chemical classification system for drugs [9] . They include the dates and reimbursed fees from any healthcare provider (physicians, paramedical services, and pharmacies), detailed costs for diagnostics (eg, radiology, laboratory, pathology), drugs, and devices. Reimbursement of hospitalization costs is by flat charge based on diagnosis-related groups [10] . Cost assessments are from the health insurer's perspective and represent charges to health insurers that were converted from Swiss francs to US dollars, using the mean conversion rates for 2012 and 2013 of 1.06 and 1.07, respectively. For this pilot study we merged claims data from Helsana, the largest health insurer in Switzerland with >1.9 million insured persons.
Privacy-preserving Probabilistic Record Linkage
Privacy-preserving probabilistic record linkage guarantees policyholder and patient confidentiality [11] . All policyholders from Helsana with an ART record (n = 2355) and patients from the SHCS receiving ART (n = 9326) during 2012 and or 2013 were considered for data linkage based on the matching variables date of birth, sex, SHCS center, and ART medication. Each variable was encrypted by data managers from Helsana and the SHCS using Bloom filters. Two sets of link files, each with anonymous identification numbers for Helsana policyholders and SHCS participants, were created and sent to an independent biostatistician, who performed the record linkage and created the link table (Supplementary Figure 1) [11] . We only considered matched pairs of patients from both data sets with all fully identical variables. That is, we did not allow for a mismatch in any antiretroviral drug. In the case of multiple identical pairs, we randomly selected 1 pair. Based on the linked data pairs the final merged data set was then constructed.
Primary End Points
The primary end points are total healthcare costs (ie, ambulatory, hospitalization, HIV related or non-HIV related) per year per patient, during 2012 and 2013 in the HIV-infected population of Switzerland, and in relation to patient characteristics and CD4 cell counts at presentation.
Statistical Methods
To account for patients with new HIV infections who entered the SHCS after 1 January 2012 (or 1 January 2013, for estimating 2013 costs), we used the Zhao and Tian semiparametric estimator to obtain the mean total costs, mean differences, standard errors (SEs), and 95% confidence intervals (CIs) for main cost categories [12, 13] . This estimator uses cost history and is suited for estimating mean costs that allow adjustment for censored data. Start times for costs were the beginning of the year or the date of HIV diagnosis, whichever came later. Survival time was defined as the interval from the start time until the date of death, the end of the year, or loss to follow-up, whichever came first. If the patient was lost to follow-up before the end of the year, or had HIV infection diagnosed after the beginning of the year but was alive at the end of the year, his or her survival time was censored. We present analyses for the total costs as well as subcategories of costs with and without adjustment for censoring.
To elaborate on the main factors determining differences in resource use, we aimed in our analysis at patient profiling that allowed us to clearly distinguish patient groups with notable different resource use. For these reasons, we classified patients into low, moderate, high, and unclassified risk groups for resource use using a Ward hierarchical cluster analysis based on standardized predictors [14] . Details on patient profiling and predictors that constitute the 3 risk groups are provided in Supplementary Tables 1 and 2 . In a sensitivity analysis, we evaluated the effect of subjects who could not be classified into a risk group owing to missing values for ≥1 risk factor, using multiple imputation methods [15] .
The isolated effect of late presentation on cost was investigated by means of propensity score matching for patients with CD4 cell counts ≤350/µL versus >350/µL at presentation, using the Stata teffects psmatch procedure [16, 17] and multiple imputation methods for missing covariates [18] . In additions, inverse probability weighting methods were fitted to verify the results of the propensity score matching on late presentation and on different CD4 cell count categories after adjustment for predictors, as specified in Table 1 [19] . All analyses were done with SAS (version 9.4) Stata (version 14; StataCorp), and R (R-project. org, version 3.3.0; the R Foundation) software.
RESULTS
Record-matching Procedure
In a total of 1196 pairs we found a full match for all matching variables corresponding to a matching performance of 50% of all policyholders with ART; these individuals formed the base for our analysis (Figure 1 ). At the time of analysis, a total of 9480 HIV-infected patients from the SHCS were receiving ART or started ART between 1 January 2012 and 31 December 2013. Of these patients, 570 (6%) had a new HIV infection diagnosed after 1 January 2012. The matched sample of 1196 patients was highly representative of the entire cohort of HIV-infected ART recipients with regard to key parameters, such as CD4 cell count at presentation, time since HIV infection and receiving ART, and further important patient characteristics (n = 9480) (Supplementary Table 1 ). Patients with illicit drug use were slightly overrepresented in the matched group (75% vs 69% in the entire SHCS).
Costs per Year
In 2012 and 2013, the estimated mean (SE) HIV-related and non-HIV-related total costs with adjustment for censoring were $30 462 ($582) and $30 965 ($629), respectively, and mainly accrued in ambulatory care ( Table 2 ). The mean observed costs, which do not account for partial costs from new HIV infections, were smaller, $29 621 (standard deviation, $19 841) for 2012 and $30 759 ($21 621) for 2013 ( Table 3 ). The estimated mean (SE) ambulatory costs were $28 662 ($528) for 2012 and $28 799 ($547) for 2013 and were mainly due to ART medications ( Table 2 Table 2 (except first measured CD4 and past AIDS event), ethnicity, sexual transmission risk group and presence of hepatitis C or B were included in the propensity score matching and inverse probability weighting models for late presentation. Also included were higher-order terms, such as the second-order degree of years with diagnosis of human immunodeficiency virus (HIV) infection and the interaction of years with HIV diagnosis and years receiving ART (included only in the propensity score model). c Age, sex, education, ethnicity, years since HIV diagnosis, and years receiving ART were included in the models. Table 2 ). In 2012 and 2013, a total of 18 (1.5%) patients died, and 33 (2.7%) were lost to follow-up.
Profiling of Health Resource Use
Patients were classified in 3 patient profiles of low (n = 241), moderate (n = 673) and high risk (n = 69) of increasing resource use. Patients in the low-risk group typically were more likely to be ≤59 years old (92.1%), male (81.3%), more educated (80.9%), light drinkers or nondrinkers (82.6%), and not currently using illicit drugs and had an intermediate likelihood of smoking (56%). They Triple-combination ART regimens included emtricitabine-tenofovir-efavirenz, emtricitabine-tenofovir-rilpivirin, and emtricitabine-tenofovir-elvitegravir-cobicistat. were also less likely to have experienced an AIDS event (81.7%) or a cardiovascular event (0%), to have psychiatric comorbid conditions (29%), or to have experienced virological failure (37%) and more likely to adhere to ART medication, and their median times since HIV diagnosis and receiving ART were 6.6 and 5.1 years, respectively, shorter periods than in the other groups. 
Costs of Late Presenters
The mean total costs for late presenters (CD4 cell count ≤350/µL) versus nonlate presenters were $30 239 versus $28 937, respectively, in 2012 and $30 890 versus $29 678 in 2013, based on the propensity score matching method. The mean cost difference (late presenter effect) was $1303 (95% CI (Table 1) . Costs in relation to CD4 cell count stratum at presentation are shown in Supplementary Figure 2 . HIV-related hospital costs were highest in the lowest CD4 cell count strata. With use of the inverse probability weighting method to adjust for patient characteristics, patients with CD4 cell counts 350-500/µL had somewhat lower costs.
DISCUSSION
The findings of the current study indicate that privacy-preserving probabilistic record linkage of clinical data from the SHCS with claims data from the largest Swiss Health insurer can successfully match clinical and insurant data. The matched patient sample and resource use data are likely to be representative of the entire SHCS, although, compared with the entire cohort, the sample had slightly more smokers and patients with suppressed viral load at baseline. Data linkage allowed for a very detailed analysis and characterization of patients with risk factors for high resource use and the associated costs. This is particular of relevance because comorbid conditions in this population are increasing and are often managed outside SHCS clinics. Resource use outside SHCS centers would have been practically impossible to assess systematically without data linkage. Owing to the decentralized characteristics of the Swiss health system relating to the federalistic political structure, representative resource use data are lacking.
Our results show that main costs accumulate in ambulatory HIV care, particularly for antiretroviral drugs, a finding confirmed in other countries [20] [21] [22] . Resource use increases in HIV-infected individuals with age, in those with previous AIDS events, and in those with directly or indirectly HIVrelated comorbid conditions. Patients with suboptimal adherence to ART, illicit drug and higher alcohol use, and psychiatric comorbid conditions were likely to have higher resource use. Low CD4 cell count at presentation is associated with slightly higher resource use, but differences in costs are not excessive compared with those for individuals who present earlier. Late presentation may lead to higher upfront costs, particularly for in-hospital costs, as confirmed in this study [23] .
In the current study, with a large proportion of long-term ART recipients with excellent virological control, CD4 cell count at presentation is no longer a major factor for higher costs. A longer observation period would have been needed to study the eventual long-term consequences of late presentation on suboptimal immune recovery and increased resource use. Differences in costs between patients in different CD4 cell count categories at first presentation were small, with slightly higher mean costs in those with the lowest CD4 cell counts at presentation. Overall costs increased from 2012 to 2013 by 1%, which is slightly less than the general development of health expenditure (plus 2.5%) in Switzerland, whereas the consumer price index in Switzerland decreased by 0.2% from 2012 to 2013, and by 1.2% from 2013 to 2015 [24] .
We identified only a few studies providing representative system-wide resource use data in HIV-infected populations [25, 26] . In a study in US veterans, poor ART adherence was not associated with higher total costs, but patients in long-term care and those with psychiatric comorbid conditions, substance abuse, or low CD4 cell count over time incurred higher costs [25] . In a Canadian study from British Columbia, female sex, comorbid conditions, any history of substance abuse, nonsuppressed viral load, and low CD4 cell count were associated with increased non-ART medical use [26] .
The strength of the current study is the representativeness and comprehensiveness of cost and clinical data on a national level, covering ambulatory and in-hospital resource use. Our sample size was large enough (12.5% of all ART recipients in the SHCS) to allow for detailed study of different cost components. We estimated annual costs over 2 years. This poses several problems in correctly accounting costs for new HIV infections and individuals lost to follow-up [27] . Excluding incident cases in a fixed sample, as done in many studies leads, to biased cost estimates [27] . In our cost analysis, we accounted for censoring, which led to higher cost estimates compared with unadjusted cost data. Loss-of follow-up may also lead to biased cost estimates, but this was also taken into account via censoring.
We matched claims data from only 1 health insurer (covering 15% of the Swiss population), which may be seen as a limitation. It is unlikely that this will have led to bias, because health insurers in Switzerland are not allowed to decline applicants or exclude insurants from basic mandatory insurance products based on their medical records. Given the large population covered by this insurer, it is also reasonable to assume that its healthcare premiums were competitive.
We limited our matching procedure to pairs with fully congruent data for our matching variables and did not release our strict matching criteria. In our modeling, we estimated that a 15% increase in sample size would have been possible with the use of less stringent matching criteria. Given the achieved sample size, we decided not to enlarge our sample, because we anticipated that the increase in sample size would come at the price of higher variability of costs estimates from eventual mismatches.
Owing to the high correlation of patient predictors for high resource use and to make interpretation of cost data more intelligible, we grouped patients by cluster analysis into patient risk profiles for high resource use. All patient characteristics of interest studied were highly significant when they were included as covariates in a generalized mixed model for annual costs. The clusters indicated marked differences in patients and comorbidity constellations that are more likely to be associated with higher costs, such as age, time since HIV infection and receiving ART, psychiatric comorbid condition, or substance abuse. For a considerable number of patients, there were missing values in important covariates, mainly in patients with HIV infection newly diagnosed in 2012 and 2013. Results from multiple imputations were similar to results from the complete patient data set. However, multiple imputation results are based on Rubin's rule, which requires independent random variables in each imputation, a condition that is not met in the present analysis [18] . Some patients from low-or moderate-risk profiles were reclassified to different profiles based on newly imputed values. All patients originally classified in the high-risk group remained in that group in all imputations.
For Switzerland and many other countries no representative data exist for costs and resource use for the treatment of HIV infection [28, 29] . Since the completion of this study, costs for ART have changed, because integrase inhibitors are now the most widely used antiretrovirals, and some antiretrovirals are no longer patented and are now available at lower prices. Previous studies in different European countries have shown that HIV-related costs, particularly costs of ART, are the major healthcare costs in HIV-infected patients [20] [21] [22] . Annual costs were in a similar range to those in studies from France (€20 170/y) and Germany (€22 231/y) [20, 21] . Our cost analysis is from the payer's and not the societal perspective, which may be seen as a limitation. In addition, all public hospitals in Switzerland are subsidized by cantons, and costs charged to health insurers generally represent about 50% of the true in-hospital costs.
In conclusion, in this representative subsample of SHCS patient from a pilot linkage study with claims data, ART was the major cost factor. Patient profiling allowed identification of multiple factors related to higher resource use, including age, previous AIDS, psychiatric comorbid conditions, illicit drug and alcohol use, and lower adherence to ART. Repeated matching of SHCS and claims data in a larger sample could provide essential data to model important future costs that will inform health policy making on different levels.
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